United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

apotheca company - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml -     indications:  for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever. indications:   for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae; leptospira interrogans serovar pomona; porcine parvo virus; formaldehyde; thiomersal - parenteral liquid/solution/suspension - erysipelothrix rhusiopathiae vaccine-general active 0.0 u; leptospira interrogans serovar pomona vaccine-microbial active 0.0 u; porcine parvo virus vaccine-viral active 0.0 u; formaldehyde aldehyde other 0.3 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - erysipelas - swine | leptospirosis - leptospira pomona | parvovirus | vaccine | equine rotavirus | l. interrogans serovar pomona | leptospira pomona infection | swine erysipelas

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b, canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091... - live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated leptospira, immunologicals for canidae - dogs - active immunisation of dogs from 6 weeks of age:to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,to prevent clinical signs, infection and urinary excretion caused by l. interrogans serogroup australis serovar bratislava,to prevent clinical signs and urinary excretion and reduce infection caused by l. interrogans serogroup canicola serovar canicola and l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae and to prevent clinical signs and reduce infection and urinary excretion caused by l. interrogans serogroup grippotyphosa serovar grippotyphosa.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b, canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091... - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inactivated leptospira, immunologicals for canidae - dogs - active immunisation of dogs from 8–9 weeks of age:to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,to prevent clinical signs, infection and urinary excretion caused by l. interrogans serogroup australis serovar bratislava,to prevent clinical signs and urinary excretion and reduce infection caused by l. interrogans serogroup canicola serovar canicola and l. interrogans serogroup icterohaemorrhagie serovar icterohaemorrhagiae,to prevent clinical signs and reduce infection and urinary excretion caused by l. interrogans serogroup grippotyphosa serovar grippotyphosa and to prevent mortality, clinical signs and infection caused by rabies virus.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parainfluenza type 2; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parainfluenza type 2 vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | parvovirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine distemper | canine parvovirus | parvovirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - canine parvovirus (inactivated); thiomersal - parenteral liquid/solution/suspension - canine parvovirus (inactivated) vaccine-viral active 0.0 u; thiomersal mercury other 0.1 mg/ml - immunotherapy - dog | bitch | castrate | puppy - canine parvovirus | parvovirus

Australia - English - Department of Health (Therapeutic Goods Administration)

biomerieux australia pty ltd - ct767 - parvovirus b19 ivds - the parvovirus b19 r-gene kit, using the real-time pcr technology after extraction of the viral dna, enables to detect and quantify the genome of parvovirus b19 in whole blood, plasma and bone marrow. combined with other biological investigation methods, the result obtained with the parvovirus b19 r-gene kit are an aid to the diagnosis and monitoring of parvovirus b19 infections in patients at risk or showing pathological condition suggesting a parvovirus b19 infection. this kit cannot be used for screening donors.